Improvement of insulin sensitivity and β‐cell function by nateglinide and repaglinide in type 2 diabetic patients – a randomized controlled double‐blind and double‐dummy multicentre clinical trial

Abstract

The efficacy of repaglinide and nateglinide in FBG, postprandial glucose excursion and early-phase insulin secretion is similar. But the effect of repaglinide 1.0 mg t.i.d. on HbA(1c) is stronger than that of nateglinide 90 mg t.i.d.. This trial had shown that nateglinide and repaglinide could comparably improve insulin sensitivity and beta-cell function.